Article
Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non-valvular atrial fibrillation.
Biopharmaceutics & drug disposition - 1 Aug 2022
Zhang Dan, Qin Wei, Du Wenwen, Wang Xiaoxing, Chen Wenqian, Li Pengmei
Abstract excerpt
Hemorrhage events occur most frequently in anticoagulant therapy for non-valvular atrial fibrillation (NVAF). Rivaroxaban is used widely for routine anticoagulation care. Genetic polymorphisms are thought to contribute to the wide intraindividual variability seen in rivaroxaban metabolism and the anticoagulant response. The aim of this study was to evaluate the effect of drug transport related single-nucleotide...
Topics
Join the communities discussing this publication.
